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Recent evidence has suggested that allogeneic engraftment failure
of puriﬁed hematopoietic stem cells (HSC) can be decreased by
including a BM-derived CD8/TCR- facilitating cell (FC) or
CD8

/TCR T cell populations. Therefore, the present study
investigated the clinically important question of GVHD effector
activity of these donor CD8 populations in the setting of HSC
transplantation. METHODS: A puriﬁed cell component-based
model of lethal GVHD was established using a P3 F1
(B63 B6D2F1) murine model. All recipients were lethally irradi-
ated and reconstituted with as few as 2000 puriﬁed HSC (Sca
ckit Lin-) of donor alone or together with one of the following
lymphoid subsets: 1) TCR splenic T cells; 2) CD8/TCR
BM-derived T cells (TBM) and 3) the CD8/TCR- FC popu-
lation. RESULTS: As expected, all recipients of puriﬁed HSC
exhibited little evidence of GVHD with clinical scores of 1.60.3,
on a ﬁve parameter clinical scale ranging from 0 to 10. Addition of
puriﬁed TCR splenocytes in the donor inoculum, as a positive
effector control, resulted in lethal GVHD with a 50% mortality
and a clinical score of 4.30.9. Similarly, recipients of HSC plus
BM-derived CD8 T cells rapidly exhibited lethal GVHD with
decreased survival and signiﬁcant morbidity (4.30.7). In marked
contrast, no clinical evidence of GVHD was present in recipients
of HSCFC (1.550.1). Histological analysis of the gut demon-
strated minimal to no evidence of GVHD in 85% of these recip-
ients whereas 57% of HSCTBM demonstrated moderate to se-
vere GVHD. CONCLUSION: These ﬁndings suggest that in
contrast to CD8 TBM, the FC, which expresses a unique FCp33-
TCR heterodimer in place of TCR, does not result in signif-
icant GVHD even in an aggressive P3 F1 model. Therefore,
supplementation of the donor inoculum with the FC has the
potential to offer a safer, more efﬁcient approach to enhance




RAPID CONVERSION TO FULL CHIMERISM AFTER REDUCED INTENSITY
CONDITIONING (RIC) AND TRANSPLANTATION OF T-CELL DEPLETED
LARGE NUMBERS OF CD34 STEM AND CD56 NATURAL KILLER
(NK) CELLS OBTAINED FROM MOBILIZED HAPLOIDENTICAL DONORS
Benaim, E., Hale, G., Horwitz, E., Leung, W., Woodard, P., Yusuf, U.,
Handgretinger, R. St Jude Children’s Research Hospital, Memphis, TN.
Since alloreactive NK cells have recently been described to exert
an anti-leukemic effect, to reduce GvHD and to facilitate engraft-
ment across HLA-barriers, we have designed a protocol to pro-
mote rapid engraftment of haploidentical stem cells after Reduced
Intensity Conditioning (RIC) in patients with refractory hemato-
logical malignancies. Haploidentical donors (if available, NK-allo-
reactive donors were preferentially chosen and 5 out of 8 donors
had a constellation of NK-alloreactivity) were mobilized using
G-CSF and/or GGM-CSF. In order to cotransplant large num-
bers of CD56 NK cells together with stem cells, PBSCs were
negatively depleted of T-lymphocytes using an anti-CD3 mono-
clonal antibody conjugated to magnetic microbeads and high gra-
dient magnetic cell sorting utilizing the automated CliniMACS
device (Miltenyi Biotec).The RIC regimen included Fludarabine
(200 mg/m2), Thiotepa (10 mg/m2) and Melphalan (60 to 140
mg/m2). Rituximab (375 mg/m2) was given prior to the stem cell
infusion. Immunosuppressive regimen included Muromonab-CD3
(OKT3) and Cyclosporine or Mycophenolate mofetil. We trans-
planted 8 patients (5 AML-relapse, 1 therapy-related secondary
MDS, 1 Biphenotypic leukemia-CR2, 1 CML-blastic crisis). 5
patients have received a previous allogeneic HSCT. The mean
total MNC, CD34 and CD3 cell counts per kg infused were
8.16 x 108 (2.6 -15 x 108), 15.13 x106 (2.14-37.54 x 106) and 0.243
x 106 (0.01-0.476 x 106) respectively. The number of infused
CD56 NK cells ranged from 44 to 200 x 106/kg. All patients
achieve early 100% peripheral blood donor chimerisms with a
median of 14.5 (8-20) days. 7 patients achieve primary engraftment
(ANC  500) at a mean of 11.14 (7-14) days. One patient had only
early lymphoid engraftment. He was successfully engrafted by day
45 after repeated plasmapheresis and a stem cell boost. No early
transplant-related mortality was seen. 3 patients had transient
grade 1-2 skin GVHD that was controlled with immunosuppres-
sion and 1 patient developed liver GvHD. 5 of the 8 patients are
alive with short follow-up. Overall, patients tolerated the RIC well
and achieved very rapid chimeric engraftment. Haploidentical
transplantation of T-cell depleted PBSC after RIC might be a
therapeutic option for patients with advanced malignant diseases
and a platform for further exploiting the role of alloreactive NK
cells in the reduction of GvHD and the facilitation of engraftment
in patients with nonmalignant diseases.
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ALLOGENEIC STEM-CELL TRANSPLANTATION WITH MATCHED UNRE-
LATED DONORS IN ELDERLY PATIENTS (55-67 YEARS); AGE BY ITSELF
IS NO LONGER A CONTRAINDICATION
Shimoni, A.1, Kroger, N.2, Zander, A.R.2, Yeshurun, M.1, Hardan, I.1,
Nagler, A.1 1. Chaim Sheba Medical Center, Tel-Hashomer, Israel; 2.
University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Allogeneic stem-cell transplantation (SCT) is a potentially cura-
tive approach for patients (pts) with hematologic malignancies.
The introduction of low-intensity conditioning (LIC) regimens
reduced SCT-related toxicity and allowed treatment of elderly pts.
However, there is only limited data on the feasibility of this
approach in SCT using unrelated donors, in elderly pts over age 55
years. Thirty-ﬁve pts were included in this study. The median age
was 58 years (range, 55-67). Eleven pts were age 60 and above at
the time of SCT. Diagnoses included myeloid malignancies (n 
22); AML (n  13, 8 secondary), MDS (n  4), CML (n  3),
myeloﬁbrosis (n  2), and lymphoid malignancies (n  13); mul-
tiple myeloma (n  9) and non-Hodgkin’s lymphoma (n  4).
Conditioning regimens included ﬂudarabine (F) and busulfan (FB,
n 16), F and melphalan (FM, n 12), F and treosulfan (FT, n
5), and F and low-dose TBI (n  2). All pts were also given ATG
during conditioning. With a median follow-up of one year, 18 pts
are alive and 16 are disease-free. The 1-year OS and DFS are 46
10%, and 3311%, respectively. Five pts died of disease progres-
sion, and 12 of treatment-related causes (TRM), including acute
GVHD (n 2), infection (n 2), liver toxicity (n 3), pulmonary
toxicity (n  2), TTP (n  2), and heart failure (n  1). The
estimated risk for TRM was 379%. A limited multivariant anal-
ysis identiﬁed conditioning with FM (rather than FB or FT), and
diagnosis of lymphoid malignancy as risk factors for TRM with
hazard ratios of 21.6 (p  0.02) and 11.2 (p  0.05), respectively.
Age category was not predictive of TRM; only 2 of the 11 pts over
age 60 had TRM. Pt or donor gender and disease status at SCT
were also not signiﬁcant risk factors. Pt number and follow-up
duration are too small to assess risk factors for OS and DFS. When
only the 20 pts with myeloid malignancies conditioned with FB or
FT were analyzed, the estimated TRM, OS and DFS rates were
2811%, 6012% and 6012%, respectively. In conclusion,
SCT from unrelated donors is feasible in selected groups of elderly
patients when using LIC regimens. Toxicity is acceptable and not
signiﬁcantly different from that observed in younger patients. Fa-
vorable outcome was observed in myeloid malignancies. Age by
itself should not rule out SCT from unrelated donors.
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A COMBINATIONAL METHOD TO IDENTIFY HLA-DRB1*0401 INDIVID-
UALS FOR IMMUNOTHERAPEUTIC STUDIES
Huang, X.1, Gebe, J.A.2, Blazar, B.1, Zhou, X.1 1. University of
Minnesota Cancer Center, Department of Pediatrics, Division of Blood
and Marrow Transplantation, Minneapolis, MN; 2. Benaroya Research
Institute at Virginia Mason, Seattle, WA.
HLA-DR4 is present at high frequencies in many populations and
presents many well-characterized peptide antigens to T cells in dis-
eases including infection, autoimmune disorders, transplant rejection
and cancer. We have established a combinational, simple and eco-
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nomic method to rapidly identify HLA-DRB1*0401 individuals in the
research laboratory. The ﬁrst step was to screen peripheral blood
mononuclear cells (PBMC) with anti-HLA-DR4 antibody (0222HA)
that we identiﬁed to be speciﬁc for HLA-DR4. PBMC from 4 out of
33 healthy blood donors were stained to be positive for HLA-DR4 by
FACS analysis. The second step was to test whether HLA-DR4
positive PBMC identiﬁed by the antibody 0222HA can present In-
ﬂuenza HA peptide (PKYVKQNTLKLAT) to HLA-DRB1*0401
restricted T cell hybridoma generated in HLA-DR4 transgenic mice.
Using this assay we demonstrated that 3 out of 4 HLA-DR4 positive
PBMC could present HA peptide to T cell hybridoma as efﬁciently as
the control EBV-transformed B cells (Priess) that express HLA-
DRB1*0401, whereas the EBV-transformed B-cells (EBV26) that
express HLA-DRB1*0431 or PBMC from 5 randomly chosen donors
that were HLA-DR4 negative were unable to present HA antigen to
T cells. The third step was to subtype HLA-DR4 at a high resolution
using PCR-based sequence-speciﬁc primers. This assay conﬁrmed
that these 3 donors whose PBMC could present HA peptide to T cells
were HLA-DRB*0401 and 1 donor whose PBMC were unable to
present HA antigen was HLA-DRB1*0436. Taken together, we con-
clude that this combinational HLA-DR4 typing method was speciﬁc,
rapid, relatively cheap and suitable for research laboratories. Our
future studies will test if antigen-speciﬁc CD4 T cells generated from
HLA-DRB1*0401 individuals can be used to identify therapeutic
antigens following bone marrow transplantation.
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CORD BLOOD NATURAL KILLER T (NKT) CELLS
Dalle, J.-H.1, Menezes, J.1, Champagne, M.2, Michel, D.1 1. Labora-
tory of Immunovirology, Hoˆpital Sainte-Justine, Montreal, QC, Can-
ada; 2. Departement of Hematology-Oncology, Hoˆpital Sainte-Justine,
Montreal, QC, Canada.
In cord blood (CB) transplantation, the GVHD rate is low
despite HLA-disparity, and the rate of leukemia relapse is identical
to that of bone marrow transplantation. In a murine model, NKT
cells demonstrate a graft-versus-leukemia activity without causing
GVHD. We therefore investigated CB-natural killer-T (NKT)
cells, by comparing their phenotypic properties with those of adult
blood (AB)-NKT cells. Mononuclear cells from 12 CB and 12 AB
samples were analyzed by ﬂow cytometry after triple-staining with
MoAb against CD56, CD3 and a third MoAb. NKT cells were
deﬁned as CD3CD56 cells. The percentage of NKT cells was
5-fold lower in CB than in AB (0.35 vs 1.56%, P  0.01). CD28,
a marker of naive T-cells, was more frequently expressed on CB-
NKT cells than on AB-NKT cells (96 vs 85%, P  0.02). The
percentage of CD11c-(integrin aX subunit) positive NKT cells was
higher in CB than in AB (85 vs 45 %; P  0.001 in both). The
percentage of NKT cells expressing intracellular perforin and
granzyme B, and surface FAS-L was higher in CB than in AB (83
vs 60 %; 88 vs 51% and 71 vs 45%; P  0.04). No difference
between CB and AB-NKT cells was noted for the expression of
CD2, CD57, L-selectin, TRAIL, FAS-L, NKG2A, NKB1, and
HLA-DR. Because of their scarcity, CB-NKT cells can not be
functionally studied without prior expansion. Taken together, our
results show that CB-NKT cells are very scarce in CB and that
their phenotype resembles that of AB-NKT cells, except that a
signiﬁcantly higher percentage of CB-NKT cells express cytotox-
icity-associated proteins.
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TEN ALLELE HIGH-RESOLUTION DNA TYPING HAS A DIRECT IMPACT
ON THE DISEASE FREE SURVIVAL (DFS) IN PEDIATRIC RECIPIENTS OF
T-CELL DEPLETED (TCD) UNRELATED DONOR (URD) HEMATOPOIETIC
STEM CELL TRANSPLANT (HCT)
Prasad, V.K.1, Selvakumar, A.2, Dastigir, H.1, Boulad, F.1, Small,
T.N.1, Prockop, S.1, Dupont, B.2, O’Reilly, R.J.1, Kernan, N.A.1 1.
Pediatric BMT Service, Memorial Sloan Kettering Cancer Center, New
York, NY; 2. Human Immunogenetics, Memorial Sloan Kettering Can-
cer Center, New York, NY.
We have shown that 1) many URD pairs matched for HLA-A,
-B, and -DRB1 alleles are disparate for one or more -C and -DQB1
alleles; and 2) matching for three loci (HLA-A, -B, and -DRB1) by
molecular as opposed to serologic typing has a direct impact on the
outcome of URD HSCT. In this study we looked at the impact of
the molecular matching at HLA-C and -DQB1 in addition to
HLA-A, -B, and -DRB1 on the outcome of URD TCD HCT.
HLA typing for all ﬁve loci was available on 47 consecutive patients
18 yrs with acute leukemia (n  40); MDS (n  5) or NHL (n 
2) transplanted between 1994 and 2002. The median follow up was
19.8 (range 1 to 108) months. BM was TCD by soybean lectin
agglutination plus E-rosette (n  41) or T10B9 MoAb plus Com-
plement (n  5). One pt received TCD PBSC (Isolex plus E-ro-
sette). Pts received a myeloablative regimen including TBI in 44
pts. Using sequence speciﬁc oligonucleotide probe (SSOP) typing
and/or DNA sequencing, 26 pairs were HLA-A, -B and -DRB1 6/6
matched. Additional typing showed 73% of the 6/6 matched pairs
were also identical at -C and -DQB1 (10/10 matched) while the
remainder was disparate for one (n  4), or two (n  3) -C or
-DQB1 alleles. The DFS in HLA 6/6 (n  26) and 10/10 (n  19)
groups was 52% and 58%, respectively (pNS). DFS in the good
risk 6/6 (n  18) and 10/10 (n  12) matched pairs was 71% and
83% (p  NS), respectively. Of the remaining 28 donor-recipient
pairs, matching was 9/10 (N 10); 8/10 (N 9); 7/10 (N 6) and
6/10 (N  3). DFS in the 8/10 and 9/10 matched pairs was 43%
while the DFS in 6/10 and 7/10 matched pts was 11% (p  .05).
DFS in 4/6 and 5/6 patients without an HLA-C and -DQB1
disparity was higher (57%) than those with HLA -C and/or
-DQB1 disparity (21%). The difference did not reach statistical
signiﬁcance due to small numbers. All 10/10 patients engrafted.
Graft rejection was seen in 5% of 8-10/10 pt. Grade III/IV
AGVHD was seen in 0% of 10/10 and 10% of 8-9/10 pts. In
conclusion, in pediatric recipients of TCD-HCT matched for
HLA -A, -B and -DRB1 by high resolution typing, disparities
detected by high resolution typing of HLA-C and -DQB1 does not
impact outcome. Good risk pts who are HLA matched at 6/6 or
10/10 have a low incidence of graft failure and GVHD and have
excellent DFS (71% and 83%, respectively). In contrast, the DFS
in 5/6 and 4/6 pts with HLA -C and -DQB1 disparities is im-
pacted, such that the DFS of HLA 8-9/10 matched pairs is signif-
icantly higher than that of HLA 6-7/10 pairs (43% vs.11%, p 
0.05).
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CHIMERISM AND TOLERANCE POST IN UTERO TRANSPLANTATION
WITH ONTOGENICALLY DIFFERENT SOURCES OF STEM CELLS
Carrier, E., Moustafa, M.E., Srivastava, A.S., Nedelcu, E.E.S.M.,
Minev, B. Rebecca and John Moores UCSD Cancer Center, School of
Medicine, La Jolla, CA.
Prenatal transplantation (IUT) is a promising strategy for the
early treatment of hemoglobinopathies and genetic disorders. We
have previously demonstrated that fetal liver cells injected prena-
tally induced tolerance, while cytokine stimulated peripheral blood
stem cells induce allosensitization. In order to this hypothesis, we
have transplanted Balb/c fetuses (H-2d) at day 13-14 of gestation
with 5x103 129 embryonic, fetal liver and bone marrow stem cells
from C57BL/6J mice (H-2b) by intra-peritoneal injection. Trans-
planted mice received boosts (transplants without conditioning)
nine month after birth, by intravenous injection of 40x106 of the
corresponding cells. The pre-boost donor chimerism detected by
highly sensitive (0.01%) semi-quantitative PCR assay demon-
strated 0.1-3% of donor cells at 6 weeks and 0.2% at 9 months.
Our hypothesis is that prenatally induced allosensitization was
responsible for this decrease in donor chimerism. This was sup-
ported by the observation that cytotoxicity assay showed shift
towards immunity and the fact that postnatal injections of high
dose donor cells resulted in low level donor chimerism. We con-
clude that the low level of donor chimerism obtained after prenatal
transplantation may lead to allosensitization. The cell dose re-
quired for prenatal tolerance induction may be much higher than
that used in this experiment and relevant experiments to test this
hypothesis are in progress. Ongoing studies are pending to delin-
eate differences between embryonic, fetal and adult sources of stem
cells in chimerism and tolerance induction and will be presented.
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